Search

Your search keyword '"Takashi Hatori"' showing total 14 results
Start Over Author "Takashi Hatori" Journal pancreatology
14 results on '"Takashi Hatori"'

1. Development of a nomogram based on radiologic findings for predicting malignancy and invasiveness in intraductal papillary mucinous neoplasms of the pancreas: an international multicenter study

Author

Hyeong Seok Kim, Taesung Park, Yongkang Kim, Heonjun Park, Youngmin Han, Jin He, Christopher L. Wolfgang, Alex Blair, M. Farzan Rashid, Michael D. Kluger, Gloria H. Su, Song-Cheol Kim, Ki-Byung Song, Masakazu Yamamoto, Takashi Hatori, Ching-Yao Yang, Hiroki Yamaue, Seiko Hirono, Sohei Satoi, Tsutomu Fujii, Satoshi Hirano, Wenhui Lou, Yasushi Hashimoto, Yasuhiro Shimizu, Roberto Valente, Marco Del Chiaro, Dong Wook Choi, Seong Ho Choi, Jin Seok Heo, Fuyuhiko Motoi, Ippei Matsumoto, Woo Jung Lee, Chang Moo Kang, Yi-Ming Shyr, Shin-E. Wang, Ho-Seong Han, Yoo-Seok Yoon, Nadine C.M. van Huijgevoort, Marc G. Besselink, Masayuki Sho, Hiroaki Nagano, Sang Geol Kim, Goro Honda, Yinmo Yang, Hee Chul Yu, Jun Chul Chung, Yuichi Nagakawa, Hyung Il Seo, Hongbeom Kim, Wooil Kwon, Sun-Whe Kim, and Jin-Young Jang

Subjects
Hepatology, Endocrinology, Diabetes and Metabolism, Gastroenterology
Published
2019

2. Stenting is unnecessary in duct-to-mucosa pancreaticojejunostomy even in the normal pancreas

Author

Ken Takasaki, Akira Fukuda, Nobuhiko Harada, Toshihide Imaizumi, and Takashi Hatori

Subjects
Male, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Anastomosis, Sepsis, Blood loss, Reference Values, Pancreaticojejunostomy, Humans, Medicine, In patient, Pancreas, Pancreatic duct, Mucous Membrane, Hepatology, business.industry, Anastomosis, Surgical, Pancreatic Ducts, Gastroenterology, Middle Aged, Pancreaticoduodenectomy, medicine.disease, Surgery, medicine.anatomical_structure, Normal pancreas, Female, Stents, business, Duct (anatomy)
Abstract

Background: There is a high risk of anastomotic leakage after pancreaticojejunostomy after pancreaticoduodenectomy (PD) in patients with a normal pancreas because of the high degree of exocrine function. These PD are therefore generally performed using a stenting tube (stented method). In recent years, we have performed pancreaticojejunostomy with duct-to-mucosa anastomosis without a stenting tube (nonstented method) and obtained good results. Methods: The point of this technique is to preserve adequate patency of the pancreatic duct by carefully picking up the pancreatic duct wall with a fine atraumatic needle and monofilament thread. The results of end-to-side pancreaticojejunostomy of the normal pancreas were compared between the nonstented method (n = 109) and the stented method (n = 39). Results: There were no differences in background characteristics between the groups, including age, gender and disease. The mean duration to complete pancreaticojejunostomy was 26.6 min in the nonstented group and 29.2 min in the stented group. The mean durations of surgical procedure and intraoperative blood loss were also similar in the groups. Morbidity rates due to early postoperative complications were 20.2 and 23.1%, with pancreatic leakage occurring in 7.3 and 7.7% of patients, respectively. These differences were not statistically significant. One patient in the stented group died of sepsis following leakage of pancreaticojejunostomy. There were also no significant differences in the mean time to initiation of solid food intake or postoperative hospital stay. Conclusion: We conclude that a stenting tube is unnecessary if the duct-to-mucosa anastomosis is completely performed. This operative technique can be considered a basic procedure for pancreaticojejunostomy because of the low risk.

Published
2002

3. 7th Meeting of the Spanish Pancreatic Club

Author

Ryszard Sendur, Susanne Gangsauge, Babette Simon, J. Stachura, Ilka Vogel, Nicole Prasnikar, Władysław Bielański, Joanna Bonior, Marina Migliori, Atsutake Okamoto, Lucio Gullo, Kozue Amemiya, Roberto Corinaldesi, Nobuhiko Harada, Jong-Sun Rew, Chang Soo Park, D. Bimmler, Wieslaw W. Pawlik, Bernd Kremer, Young-Eun Joo, Donatella Santini, Masanao Okada, Christian Robbel, Doris Henne-Bruns, Riccardo Casadei, Toshihide Imaizumi, Anna Leja, Leif Jansson, Peter C. Konturek, Naoto Egawa, Nariaki Matsuura, Jolanta Jaworek, Per-Ola Carlsson, Masahiko Tsujimoto, Holger Kalthoff, Tsutomu Takeda, Tillmann Bert, Ken Takasaki, R. Graf, Yasuhiro Ito, Akihiro Munakata, Peter A. Banks, M. Schiesser, Nobuhiro Sakaki, Karin Münch, Terumi Kamisawa, Kenichi Wakasa, Alphonso Brown, Paola Tomassetti, Akira Fukuda, Romana Tomaszewska, Lawrence K. Gates, S. Lalli, Kouji Tsuruta, Jean-Daniel Baillargeon, Sei-Jong Kim, B. Jachimczak, Stanislaw J. Konturek, Hartmut Printz, Michael Hughes, Takashi Hatori, Göran Mattsson, Nikolaus Lubomierski, Laurie S. Haas, Kristin Olausson, Piotr Pierzchalski, and Yuyang Tu

Subjects
medicine.medical_specialty, Index (economics), Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Family medicine, Gastroenterology, medicine, Club, business
Published
2002

5. The treatment strategy of non-functioning pancreatic neuroendocrine tumor

Author

Toru Furukawa, Nana Oshima, Keiko Shiratori, Kazuhiko Hayashi, Ryuji Suzuki, Shuji Suzuki, Wataru Izumo, Takashi Hatori, Masakazu Yamamoto, and Akira Kimijima

Subjects
Hepatology, Pancreatic neuroendocrine tumor, business.industry, Endocrinology, Diabetes and Metabolism, Gastroenterology, Cancer research, Medicine, Treatment strategy, CA19-9, business, medicine.disease
Published
2013

7. The long-term survivors after curative resection for the pancreatic cancer should be paid attention to the remnant pancreatic cancer

Author

K. Shiratori, Shuji Suzuki, Takashi Hatori, Masayuki Yamamoto, Toru Furukawa, Kyoko Shimizu, Akira Kimijima, Nana Oshima, and Yuko Kuboki

Subjects
Curative resection, medicine.medical_specialty, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Pancreatic cancer, General surgery, Gastroenterology, medicine, medicine.disease, business, Term (time)
Published
2013

8. Clinicopathological significance of molecular aberrations in G-protein coupled receptor pathway in intraductal papillary mucinous neoplasms of the pancreas

Author

K. Shiratori, Yuko Kuboki, Masakazu Yamamoto, Kyoko Shimizu, Toru Furukawa, Takashi Hatori, and Noriyuki Shibata

Subjects
Oncology, medicine.medical_specialty, medicine.anatomical_structure, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Internal medicine, Gastroenterology, medicine, Cancer research, Pancreas, business, G protein-coupled receptor
Published
2013

9. Somatic mutations of RNF43 are associated with its aberrant expression and GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas

Author

Masanori Sugiyama, Takashi Hatori, Noriyuki Shibata, Kyoko Shimizu, Yuko Kuboki, Keiko Shiratori, Hitomi Sakamoto, Masakazu Yamamoto, and Toru Furukawa

Subjects
medicine.medical_specialty, Hepatology, biology, business.industry, Somatic cell, Endocrinology, Diabetes and Metabolism, General surgery, Gastroenterology, medicine.anatomical_structure, medicine, GNAS complex locus, biology.protein, Cancer research, Pancreas, business
Published
2014

10. Strategy for the borderline resectable pancreatic cancer using neo-adjuvant chemoradiation therapy

Author

Shuji Suzuki, Masakazu Yamamoto, Toru Furukawa, Akira Kimijima, Takashi Hatori, Keiko Shiratori, Wataru Izumo, Norio Mitsuhashi, Ryuji Suzuki, and Nana Ooshima

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Gastroenterology, Neo adjuvant, medicine.disease, Borderline resectable, Internal medicine, Pancreatic cancer, Medicine, business, Prospective cohort study
Abstract

s / Pancreatology 13 (2013) S1–S80 S10 group (1 yr; 85.8%, 3 yrs; 56.7%) and ODP group (1 yr; 79.3%, 3 yrs; 44.5%). (P 1⁄4 0.079) Conclusions: There seems to be increasing evidence that LDP is equivalent to ODP for Pancreatic cancer in terms of oncologic outcome. However, long term oncologic result will be required and further randomized prospective studies should be performed to support the validity of LDP for Pancreatic cancer.

Published
2013

11. Management of infectious complications after pancreaticoduodenectomy

Author

Masakazu Yamamoto, Nana Oshima, Wataru Izumo, Shuji Suzuki, Ryuji Suzuki, Takashi Hatori, Keiko Shiratori, and Akira Kimijima

Subjects
medicine.medical_specialty, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, General surgery, Gastroenterology, medicine, Pancreaticoduodenectomy, business
Published
2013

12. Surgical management for IPMN of the pancreas

Author

Nana Ooshima, Yuko Kuboki, Akira Kimijima, K. Shiratori, Takashi Hatori, Toru Furukawa, Shuji Suzuki, Masayuki Yamamoto, and Kyoko Shimizu

Subjects
Autophagosome, medicine.medical_specialty, Hepatology, Combination therapy, medicine.diagnostic_test, Cell growth, business.industry, Endocrinology, Diabetes and Metabolism, General surgery, Autophagy, Gastroenterology, Gemcitabine, Western blot, Chloroquine, Cancer research, medicine, Cytotoxicity, business, medicine.drug
Abstract

s / Pancreatology 13 (2013) e1–e94 e33 drugs (5-FU and gemcitabine) and a combination of both drug types. The status of autophagy in PANC-1 was evaluated by Western blot analysis of the autophagosome marker LC3-II. The effect of the drugs on cell growth was also assessed. Results: Western blot of LC3-II showed that autophagy is activated in PANC-1 under basal culture conditions, and was suppressed by chloroquine, which is known to inhibit the degradation of autophagosomes. Both 5-FU and gemcitabine induced autophagy in PANC-1. When chloroquine was added together with these anticancer drugs on PANC-1, LC3-II bands were stronger. Chloroquine suppressed cell growth of PANC-1. In addition, chloroquine greatly increased the growth-inhibiting effects of 5FU and gemcitabine. Conclusions: Autophagy contributes to cell growth and has a cytoprotective effect against anticancer drugs (5-FU and gemcitabine) in PANC1 cells. Choroquine increases the cytotoxicity of 5-FU and gemcitabine by inhibiting autophagy. Possible combination therapy of these anticancer drugs and chloroquine should be further studied.

Published
2013

13. Usefulness of cell block cytology for preoperative grading and typing of IPMN

Author

Takashi Hatori, Nana Oshima, K. Shiratori, Toru Furukawa, M. Monzen, Kyoko Shimizu, Kenta Nagao, Yukiko Takayama, and Junko Tahara

Subjects
medicine.medical_specialty, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, Cytology, Gastroenterology, medicine, Typing, Radiology, business, Grading (tumors), Cell block, Surgery
Published
2013

14. Does duodenum-preserivng pancreatectomy prevent severe postoperative fatty liver?

Author

Toru Furukawa, Shuji Suzuki, K. Shiratori, Katsutoshi Tokushige, Akira Kimijima, E. Hashimoto, Nana Ooshima, Masayuki Yamamoto, M. Taniai, Kyoko Shimizu, and Takashi Hatori

Subjects
medicine.medical_specialty, Hepatology, business.industry, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Fatty liver, Gastroenterology, medicine.disease, medicine.anatomical_structure, Internal medicine, Pancreatectomy, medicine, Duodenum, business
Published
2013

Catalog

Books, media, physical & digital resources
See catalog results